Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1

ObjectivesImmune checkpoint inhibitors (ICIs) of programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) have been rapidly adopted in US clinical practice for first-line therapy of metastatic non-small cell lung cancer (NSCLC) since regulatory approval in October 2016, and a better under...

Full description

Bibliographic Details
Main Authors: Vamsidhar Velcheti, Xiaohan Hu, Lingfeng Yang, M. Catherine Pietanza, Thomas Burke
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer (NSCLC)
manual chart review
observational study
pembrolizumab
real-world progression-free survival (rwPFS)
overall survival (OS)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.834761/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.834761/full

Similar Items